We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
Read MoreHide Full Article
Key Takeaways
Editas posts a Q3 loss of $0.28 per share, beating estimates and improving from last year's $0.75 loss.
Revenues jump to $7.5M, driven by milestone payment recognition from the Bristol Myers collaboration.
Editas designates EDIT-401 as its lead in vivo gene-editing therapy targeting LDL cholesterol reduction.
Editas Medicine (EDIT - Free Report) reported a loss of 28 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 38 cents. The company had incurred a loss of 75 cents per share in the year-ago quarter.
Collaboration and other research and development (R&D) revenues, which comprise Editas’ top line, were $7.5 million in the reported quarter, up significantly from the year-ago quarter’s figure. The reported figure comprehensively beat the Zacks Consensus Estimate of $2 million. The increase is primarily due to the recognition of revenues related to a milestone achievement under a collaboration agreement with Bristol Myers.
EDIT’s Q3 Results in Detail
In the third quarter of 2025, R&D expenses decreased 58% to $19.8 million compared with $47.6 million reported in the year-ago period. The downtick in R&D expenses is mainly due to lower clinical and manufacturing costs following the abandonment of the reni-cel program in December 2024, partly offset by costs of in vivo research and discovery.
General and administrative expenses were $12.3 million in the reported quarter, down 32% year over year, due to a decrease in employee-related expenses because of reduced workforce following the abandonment of the reni-cel program.
EDIT did not record any restructuring and impairment charges in the reported quarter.
Shares of Editas have rallied 98.5% year to date compared with the industry’s 11.2% growth.
Image Source: Zacks Investment Research
Editas had cash, cash equivalents and investments worth $165.6 million as of Sept. 30, 2025, down from $178.5 million as of June 30, 2025. The company expects that its existing cash position, together with $17.3 million in ATM proceeds raised after Sept. 30, 2025, and retained payments from its Vertex license agreement, will fund operating and capital needs into the third quarter of 2027.
EDIT’s Key Pipeline Update
Editas has no approved products in its portfolio at the moment. Therefore, pipeline development remains the key focus of the company.
In December 2024, Editas ended the reni-cel development program following the failure of an extensive search to yield a commercial partner. As a result of this decision, the company implemented cost-saving measures, including a workforce reduction of approximately 65%. The move reverted EDIT to the pre-clinical stage. As part of its strategic reprioritization efforts, Editas has focused its workforce and resources on in vivo (within the living organism) pipeline development.
In September, Editas nominated EDIT-401 as its lead in vivo development candidate. This experimental, potential best-in-class, one-time gene editing therapy is designed to significantly reduce LDL cholesterol (LDL-C) levels, marking a key milestone in the company’s efforts to advance in vivo programmable gene editing.
Editas has already reported compelling preclinical results for EDIT-401, showing rapid and durable ≥90% LDL-C reductions in both non-human primates and mouse models with only moderate LDLR editing. The data showed a six-fold or more increase in hepatic LDLR protein and sustained lipid lowering over three months.
Editas remains on track to file an investigational new drug or clinical trial application by mid-2026 and targets initial in-human proof-of-concept data for EDIT-401 by year-end 2026.
Editas Medicine, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $7.25 to $7.29 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 63.2%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, the average surprise being 21.24%.
In the past 60 days, estimates for Arcutis Biotherapeutics’ loss per share have narrowed from 44 cents to 24 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 9 cents to 41 cents. Year to date, shares of ARQT have rallied 80.1%.
Arcutis Biotherapeutics’ earnings beat estimates in each of the trailing four quarters, the average surprise being 64.80%.
In the past 60 days, estimates for ADMA Biologics’ earnings per share have increased from 57 cents to 58 cents for 2025. During the same time, earnings per share estimates for 2026 have improved from 88 cents to 90 cents. Year to date, shares of ADMA have gained 11%.
ADMA Biologics’ earnings beat estimates in one of the trailing four quarters, matched once and missed the same on the remaining two occasions, with the average negative surprise being 3.01%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
Key Takeaways
Editas Medicine (EDIT - Free Report) reported a loss of 28 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 38 cents. The company had incurred a loss of 75 cents per share in the year-ago quarter.
Collaboration and other research and development (R&D) revenues, which comprise Editas’ top line, were $7.5 million in the reported quarter, up significantly from the year-ago quarter’s figure. The reported figure comprehensively beat the Zacks Consensus Estimate of $2 million. The increase is primarily due to the recognition of revenues related to a milestone achievement under a collaboration agreement with Bristol Myers.
EDIT’s Q3 Results in Detail
In the third quarter of 2025, R&D expenses decreased 58% to $19.8 million compared with $47.6 million reported in the year-ago period. The downtick in R&D expenses is mainly due to lower clinical and manufacturing costs following the abandonment of the reni-cel program in December 2024, partly offset by costs of in vivo research and discovery.
General and administrative expenses were $12.3 million in the reported quarter, down 32% year over year, due to a decrease in employee-related expenses because of reduced workforce following the abandonment of the reni-cel program.
EDIT did not record any restructuring and impairment charges in the reported quarter.
Shares of Editas have rallied 98.5% year to date compared with the industry’s 11.2% growth.
Image Source: Zacks Investment Research
Editas had cash, cash equivalents and investments worth $165.6 million as of Sept. 30, 2025, down from $178.5 million as of June 30, 2025. The company expects that its existing cash position, together with $17.3 million in ATM proceeds raised after Sept. 30, 2025, and retained payments from its Vertex license agreement, will fund operating and capital needs into the third quarter of 2027.
EDIT’s Key Pipeline Update
Editas has no approved products in its portfolio at the moment. Therefore, pipeline development remains the key focus of the company.
In December 2024, Editas ended the reni-cel development program following the failure of an extensive search to yield a commercial partner. As a result of this decision, the company implemented cost-saving measures, including a workforce reduction of approximately 65%. The move reverted EDIT to the pre-clinical stage. As part of its strategic reprioritization efforts, Editas has focused its workforce and resources on in vivo (within the living organism) pipeline development.
In September, Editas nominated EDIT-401 as its lead in vivo development candidate. This experimental, potential best-in-class, one-time gene editing therapy is designed to significantly reduce LDL cholesterol (LDL-C) levels, marking a key milestone in the company’s efforts to advance in vivo programmable gene editing.
Editas has already reported compelling preclinical results for EDIT-401, showing rapid and durable ≥90% LDL-C reductions in both non-human primates and mouse models with only moderate LDLR editing. The data showed a six-fold or more increase in hepatic LDLR protein and sustained lipid lowering over three months.
Editas remains on track to file an investigational new drug or clinical trial application by mid-2026 and targets initial in-human proof-of-concept data for EDIT-401 by year-end 2026.
Editas Medicine, Inc. Price, Consensus and EPS Surprise
Editas Medicine, Inc. price-consensus-eps-surprise-chart | Editas Medicine, Inc. Quote
EDIT’s Zacks Rank & Stocks to Consider
Editas currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals (ANIP - Free Report) , Arcutis Biotherapeutics (ARQT - Free Report) and ADMA Biologics (ADMA - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $7.25 to $7.29 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 63.2%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, the average surprise being 21.24%.
In the past 60 days, estimates for Arcutis Biotherapeutics’ loss per share have narrowed from 44 cents to 24 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 9 cents to 41 cents. Year to date, shares of ARQT have rallied 80.1%.
Arcutis Biotherapeutics’ earnings beat estimates in each of the trailing four quarters, the average surprise being 64.80%.
In the past 60 days, estimates for ADMA Biologics’ earnings per share have increased from 57 cents to 58 cents for 2025. During the same time, earnings per share estimates for 2026 have improved from 88 cents to 90 cents. Year to date, shares of ADMA have gained 11%.
ADMA Biologics’ earnings beat estimates in one of the trailing four quarters, matched once and missed the same on the remaining two occasions, with the average negative surprise being 3.01%.